NORTHWEST BIOTHERAPEUTICS INC

Northwest Biotherapeutics addressed rumors alleging the rejection of its Marketing Authorization Application (MAA) for DCVax-L for glioblastoma by the Medicines and Healthcare Products Regulatory Agency (MHRA). The company confirmed with the MHRA that the application remains under initial regulatory review, has not been refused or withdrawn, and continues to progress. Northwest Biotherapeutics categorically refutes these false rumors, suggesting they may be linked to stock manipulation following positive Phase 3 trial data.

Northwest Biotherapeutics reported a net loss of $3.1 million for Q1 2026, a significant improvement from $19.3 million in Q1 2025. Revenues increased to $0.5 million, while operating expenses decreased. Despite these improvements, the company disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash flow deficits. The Marketing Authorization Application for DCVax®-L for glioblastoma is currently under MHRA review in the U.K.

NORTHWEST BIOTHERAPEUTICS INC filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The filing disclosed that as of March 31, 2026, the company had 1,606,857,011 shares of common stock outstanding. Additionally, the aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $340,239,000 as of June 30, 2025.